Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure
Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure
复制标题
DOI：
10.1136/gutjnl-2014-308943
复制
发表时间：
2015-08-01
期刊：
影响因子：
24.5
通讯作者：
Zoulim, Fabien
中科院分区：
文献类型：
--
作者：
Zeisel, Mirjam B.;Lucifora, Julie;Zoulim, Fabien
乙型肝炎病毒感染是肝硬化和肝细胞癌的主要原因。尽管可以通过疫苗接种有效预防乙型肝炎病毒感染，并且可以进行治疗，但迄今为止，全球范围内超过 2.4 亿的慢性感染者还没有可靠的治疗方法。目前的治疗只能实现病毒抑制，大多数感染者需要终身治疗。在法国国家艾滋病和病毒性肝炎研究机构“HBV 治愈”计划的框架内，2014 年 6 月在巴黎举办了一次科学研讨会，以明确有关 HBV 病理学的最新技术和尚未解答的问题，并制定针对 HBV 治愈的协调一致的策略。这篇综述总结了我们目前对导致病毒持续存在的 HBV 宿主相互作用的理解，以及最终解决慢性 HBV 感染治疗中未满足的医疗需求需要克服的障碍。
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.